Literature DB >> 16278474

Parameters for treatment decisions for salvage radiation therapy.

Shelly Bowers Hayes1, Alan Pollack.   

Abstract

Radical prostatectomy (RP) is the most common primary treatment for prostate cancer. About 40% of those with high-risk pathologic features, such as a positive margin or seminal vesicle involvement, will develop biochemical failure at some point in the future. Radiotherapy (RT), with or without concurrent androgen deprivation, has been used liberally in the management of men with a rising prostate-specific antigen (PSA) after RP, based mostly on relatively small retrospective series. Factors such as the prostatectomy Gleason score, seminal vesicle invasion, absolute pre-RT PSA level, and pre-RT PSA doubling time are emerging as important determinants of outcome after RT. These factors should be used as a guide to the options of local therapy alone (RT), local therapy plus systemic therapy (typically androgen deprivation therapy), and systemic therapy alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16278474     DOI: 10.1200/JCO.2005.03.1575

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

Review 1.  [Recurrence of prostate cancer--value of salvage radiotherapy].

Authors:  C Belka; U Ganswindt
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

2. 

Authors:  Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

3.  Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis.

Authors:  T N Showalter; K A Foley; E Jutkowitz; C D Lallas; E J Trabulsi; L G Gomella; A P Dicker; L T Pizzi
Journal:  Ann Oncol       Date:  2011-06-09       Impact factor: 32.976

4.  Treatment results of adjuvant radiotherapy and salvage radiotherapy after radical prostatectomy for prostate cancer.

Authors:  Koichi Wadasaki; Yuko Kaneyasu; Masahiro Kenjo; Kanji Matsuura; Yuji Murakami; Yasutoshi Hashimoto; Katsuhide Ito; Hiroshi Kiriu; Atsushi Ito
Journal:  Int J Clin Oncol       Date:  2007-02-25       Impact factor: 3.402

5.  A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses.

Authors:  Przemyslaw Twardowski; Noriko Kanaya; Paul Frankel; Timothy Synold; Christopher Ruel; Sumanta K Pal; Maribel Junqueira; Manisha Prajapati; Tina Moore; Pamela Tryon; Shiuan Chen
Journal:  Cancer       Date:  2015-05-18       Impact factor: 6.860

6.  Definition and visualisation of regions of interest in post-prostatectomy image-guided intensity modulated radiotherapy.

Authors:  Linda J Bell; Jennifer Cox; Thomas Eade; Marianne Rinks; Andrew Kneebone
Journal:  J Med Radiat Sci       Date:  2014-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.